Integrin-linked kinase mRNA (ILK mRNA) (ILK mRNA)

Integrin-linked kinase (ILK) mRNA encodes a multifunctional protein that serves as both a scaffold and a putative serine/threonine kinase at focal adhesions, linking the extracellular matrix to the actin cytoskeleton (UniProt Q13418). ILK is a central component of the ILK-PINCH-Parvin (IPP) complex, which regulates essential cellular processes such as cell shape, motility, and survival signaling through the PI3K/Akt and Wnt/beta-catenin pathways (PubMed 21858014). Targeting the ILK mRNA using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) is a therapeutic strategy designed to deplete the total pool of ILK protein, thereby disrupting both its catalytic activity and its critical scaffolding functions (PubMed 11060331). Overexpression of ILK mRNA is frequently observed in various malignancies, including breast, prostate, and colon cancers, where it is associated with poor prognosis, epithelial-mesenchymal transition (EMT), and increased metastatic potential (PubMed 16110615). Beyond oncology, ILK mRNA is investigated as a target in chronic kidney disease and cardiac hypertrophy, as its dysregulation contributes to pathological tissue remodeling and fibrosis (PubMed 24333696). Experimental knockdown of ILK mRNA has been shown to induce apoptosis and enhance the sensitivity of tumor cells to conventional chemotherapeutic agents in preclinical models.

Other names

ILK1 mRNAP59 mRNAIntegrin-linked protein kinase mRNA

Antisense-mediated mRNA degradation and RNA interference (RNAi) leading to the knockdown of ILK protein synthesis.